News Releases

November 15, 2019
Unum Therapeutics to Present at Upcoming Investor Conference
CAMBRIDGE, Mass. , Nov. 15, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced its participation in the following upcoming investor conference: Piper Jaffray 31 st
November 12, 2019
Unum Therapeutics Reports Third Quarter 2019 Financial Results
- Progress towards focusing on solid tumors remains on track with enrollment and early safety updates from Phase 1 trial of ACTR707 in HER2+ cancers expected by the end of this year- CAMBRIDGE, Mass. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc.
November 5, 2019
Unum Therapeutics Presents Preclinical Data for BOXR1030 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
- Unum’s first product candidate from its BOXR platform, BOXR1030, is designed to improve T cell functionality in the solid tumor microenvironment -             - BOXR1030 T cells co-express the GOT2 transgene to improve T cell metabolism and reduce T cell exhaustion, leading to complete tumor
November 4, 2019
Unum Therapeutics Announces Strategic Focus on Developing Best-in-Class Cellular Therapies for Solid Tumor Cancers
- Solid tumor cancers represent the greatest unmet medical need for targeted cell therapies; Unum’s goals are to more selectively target solid tumors with its ACTR platform candidates and improve T cell functionality in the solid tumor microenvironment with its BOXR platform candidates - -
October 2, 2019
Unum Therapeutics Announces Data Presentation at the Upcoming Society for Immunotherapy of Cancer (SITC) Meeting
CAMBRIDGE, Mass. , Oct. 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced acceptance of a presentation at the 34 th annual meeting of the Society for Immunotherapy
September 5, 2019
Unum Therapeutics to Present at Upcoming Industry Conferences in September
CAMBRIDGE, Mass. , Sept. 05, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced its participation in the following industry conferences in September: Cell & Gene Therapy
August 26, 2019
Unum Therapeutics to Present at Upcoming September Investor Conferences
CAMBRIDGE, Mass. , Aug. 26, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced that Charles Wilson , Ph.D., President and Chief Executive Officer, will present at two
August 12, 2019
Unum Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Updates
- Updated results from Phase 1 trial with ACTR707 in combination with rituximab in adults with relapsed/refractory non-Hodgkin lymphoma confirms the clinical activity achieved in previous cohorts with no adverse events of cytokine release syndrome or severe neurotoxicity –                     
August 2, 2019
Unum Therapeutics to Review Second Quarter 2019 Financial Results on August 12, 2019
CAMBRIDGE, Mass. , Aug. 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq: UMRX), a biopharmaceutical company focused on developing potentially curative cellular immunotherapies through its ACTR and BOXR platforms, today announced that the company will host a conference call and live
July 29, 2019
Unum Therapeutics Announces New Appointments to its Board of Directors
CAMBRIDGE, Mass. , July 29, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer based on its novel T cell technology platforms, ACTR and BOXR, today announced the
Displaying 1 - 10 of 22
The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Unum disavows any obligation to update the information contained in such press releases after the date of their issuance.